Wockhardt Reports 1% QoQ Growth in Q1FY26, Showcases Progress in Novel Antibiotics and Biosimilars

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its Q1 results for Financial Year 2025-26. The company recorded a 1% QoQ growth in revenue and EBITDA. The company's business approach focuses on growth momentum, profitability, and innovation, with a particular focus on its novel antibiotics and diabetes biosimilars portfolio. The company has made significant progress in its novel antibiotic ZAYNICH®, with global Phase III clinical studies completed and pre-NDA submission meetings held with the US FDA. The company has also launched Mignaf® in India, which has received encouraging responses from clinicians. Wockhardt has also made strides in its USFDA-approved antibiotic Emrok, with a landmark publication in a reputed UK medical journal highlighting its effectiveness in treating nearly untreatable cases of bone and joint infections.